Business Context and Reporting Period
Sono-Tek Corporation designs and manufactures ultrasonic coating systems and related components for electronics, medical, alternative energy, industrial, and other markets. This unaudited Form 10-Q covers the quarter and nine months ended November 30, 2019, the third quarter and first nine months of fiscal 2020; comparisons are to the corresponding 2018 periods. The company reports that most equipment revenue is recognized when customers take control of the equipment.
Financial Performance and Position
| Metric | Three months ended Nov. 30, 2019 | Nine months ended Nov. 30, 2019 |
|---|---|---|
| Net sales | $3.672 million, up 16% | $9.841 million, up 13% |
| Gross profit / margin | $1.797 million / 48.9% | $4.649 million / 47.2% |
| Operating income / margin | $270,000 / 7.4% | $367,000 / 3.7% |
| Net income | $280,000 | $420,000 |
| Basic and diluted EPS | $0.02 | $0.03 |
- For the nine months, operating cash flow was $1.023 million, investing cash flow was negative $1.767 million, and financing cash flow was negative $122,000. Cash and cash equivalents declined $865,000 to $2.280 million.
- Cash plus marketable securities totaled $6.019 million at November 30, up $509,000 from February 28. Marketable securities were $3.740 million.
- Working capital was $6.696 million. Current assets were $10.530 million and current liabilities were $3.834 million.
- Total debt was $749,000, including $168,000 current and $581,000 long-term. The $1.5 million revolving line had no outstanding borrowings; $659,000 was committed to customer letters of credit, leaving $841,000 unused. The mortgage bears 4.15% interest and is payable through January 2024.
- Inventory increased to $2.979 million from $1.658 million at February 28, primarily to support orders. Customer deposits increased to $1.954 million from $1.150 million.
Material Changes Versus Prior Comparable Period
- Quarterly net sales increased $517,000; higher integrated coating system sales and SonoBraze sales for heat-exchanger and condenser manufacturing contributed. For the nine months, growth was led by semiconductor, stent-coating, and float-glass equipment sales.
- Gross margin rose from 41.1% to 48.9% for the quarter and from 45.1% to 47.2% year to date. Management attributed improvement to product and geographic mix, including fewer sales in China, and stronger sales of higher-margin systems.
- Operating income rose from $50,000 to $270,000 for the quarter and from $96,000 to $367,000 for the nine months. Operating expenses increased 23% and 12%, respectively, with marketing and selling costs the largest increase.
- Net income rose from $20,000 to $280,000 for the quarter and from $101,000 to $420,000 year to date. The prior-year periods included unrealized marketable-securities losses of $59,000 for the quarter and $189,000 for the nine months; none was recorded in the current periods.
- Backlog was $5.402 million at November 30, up 78% from $3.038 million at February 28. Approximately 65% of sales originated outside the U.S. and Canada, compared with 62% in the prior-year periods.
Outlook, Commentary, and Risks
- Management expected fiscal 2020 sales growth of 15%–25% based on existing backlog, with higher sales volume expected to expand margins and strengthen earnings. It expected a significant portion of the November 30 backlog to ship by fiscal year-end.
- Management identified customer acceptance-test schedules for complex, customized equipment as a factor affecting shipment timing. Outlook also included a $1.65 million order for the OMNIbot robotic coating platform.
- Management cited risks including economic and competitive conditions, tariffs, product development and customer acceptance, financing and capacity, backlog conversion, on-time completion of large orders, and the shift toward more complex complete-machine solutions.
- The filing reported no material commitments or contingencies other than customer letters of credit, no legal proceedings, and no material impact from adoption of the discussed lease and tax accounting standards. Disclosure controls were reported effective, with no material quarterly change in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether the $5.402 million backlog converts to shipments and revenue on the expected schedule, particularly given customer acceptance testing and the large OMNIbot order.
- Whether improved gross margins persist as product and geographic mix change, including exposure to China, tariffs, and the higher-margin systems cited by management.
- Whether rising inventory and customer deposits reflect executable orders and are managed without creating working-capital or delivery pressures.
- The availability and terms of the revolving credit line: $659,000 supports letters of credit, while $841,000 was reported unused and there were no revolver borrowings.
- Whether projected 15%–25% fiscal-year sales growth and stronger earnings are achieved; the filing presents these as expectations, not guarantees.